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Basic functions of nitric oxide
Nitric oxide (NO) is a short-lived signaling molecule that 
plays an important role in a variety of physiologic 
functions, including the regulation of blood vessel tone, 
inﬂ   ammation, mitochondrial functions and apoptosis 
[1,2]. NO was originally identiﬁ   ed as endothelium-
derived relaxant factor based on the observations of 
Furchgott and Zawadzki [3]. Th   ey observed that 
acethylcholine-induced blood vessel relaxation occurred 
only if the endothelium was intact. Some years later, the 
endothelium-derived relax  ant factor was identiﬁ  ed  as 
NO [4]. NO is synthesized from L-arginine by NO 
synthetases (NOSs): neuronal NOS (nNOS), inducible 
NOS (iNOS), and endothelial NOS (eNOS) [5]. NO also 
serves as a potent immuno  regulatory factor, and inﬂ  u-
ences the cytoplasmic redox balance through the genera-
tion of peroxynitrite (ONOO-) following its reaction with 
superoxide (O2
-) [6]. In addition, NO regu  lates signal 
transduction by regulating Ca2+ signaling, by regulating 
the structure of the immuno  logical synapse, or through 
the modiﬁ   cation of intra  cellular proteins, such as by 
inter  actions with heme groups (Figure 1). Here we 
summarize the eﬀ  ects of NO on T lymphocyte functions 
in both systemic lupus erythe  matosus (SLE) and rheuma-
toid arthritis (RA).
NO regulates mitochondrial membrane potential in 
human T cells [7], and may both stimulate and inhibit 
apop  tosis [8]. It was shown to inhibit cytochrome c 
oxidase, leading to cell death through ATP depletion 
(Figure  1). In addition, NO was shown to regulate 
mitochondrial biogenesis in U937 and HeLa cells and 
adipocytes through the cGMP-dependent peroxisome 
proliferator-activating receptor λ coactivator 1α [9]. 
According to our earlier work, NO regulates mito  chon-
drial biogenesis in human lymphocytes as well [10]. 
Nitrosylation of sulfhydryl groups represents an impor-
tant cGMP-independent, NO-dependent post-trans-
lational modiﬁ  cation. Several important signal transduc-
tion proteins are potential targets of S-nitrosylation, such 
as caspases and c-Jun-N-terminal kinase (JNK) [11,12].
The role of nitric oxide in T cell activation and 
diff  erentiation
NO regulates T lymphocyte function in several ways: 
T cell activation is associated with NO production and 
mitochondrial hyperpolarization (MHP) [13]. According 
to our previous data, eNOS and nNOS are expressed in 
human peripheral blood lymphocytes and both are up-
regulated several times following T cell activation [13]. 
TCR stimulation induces Ca2+  inﬂ  ux  and,  through 
inositol-1,4,5-triphosphate (IP3), the release of Ca2+ from 
intracellular stores. Th  e  IP3  inhibitor 2-APB 
(2-aminoethoxydiphenyl borane) decreases T-cell-
activation-induced Ca2+ and NO production, and NO 
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© 2010 BioMed Central Ltdtreatment of T lymphocytes leads to an increase in mito-
chondrial and cytoplasmic Ca2+ levels. In contrast, th  e 
NO che  lator C-PTIO (carboxy-2-phenyl-4,4,5,5-tetra-
methyl-imidazoline-1-oxyl-3-oxide) powerfully inhibits 
the T-cell-activation-induced Ca2+ response, NO produc-
tion and MHP, indicating that T cell receptor (TCR)-
activation-induced MHP is mediated by NO [13].
A central event in the antigen-speciﬁ  c interaction of 
T cells with antigen-presenting cells is the formation of 
the immunological synapse, in which the TCR complex 
and the adhesion receptor LFA-1 (leukocyte function-
associated antigen 1) are organized in central and 
peripheral supramolecular activation clusters. eNOS was 
shown to translocate with the Golgi apparatus to the 
immune synapse of T helper cells engaged with antigen-
presenting cells [14] (Figure 1). Overexpression of eNOS 
was associated with increased phosphorylation of the 
CD3ζ chain, ZAP-70, and extracellular signal-regulated 
kinases, and increased IFN-γ synthesis, but reduced pro-
duc  tion of IL-2. Th  ese data indicate that eNOS-derived 
NO selectively potentiates T cell receptor signaling to 
antigen at the immunological synapse [14].
Following activation, CD4 T cells proliferate and 
diﬀ  erentiate into two main subsets of primary eﬀ  ector 
Figure 1. Schematic diagram of T cell activation, nitric oxide production, and mitochondrial hyperpolarization. Nitric oxide (NO) is 
produced in the cytosol, the mitochondrial membrane, and at the immunological synapse of T cells. Localized NO production has been linked to 
targeting of endothelial NO synthase (eNOS) to the outer mitochondrial membrane and to the T-cell synapse. NO regulates many steps of T cell 
activation, the production of cytokines, such as IL-2, and mitochondrial hyperpolarization and mitochondrial biogenesis. NO regulates mammalian 
target of rapamycin (mTOR) activity. NO dependent mTOR activation induces the loss of TCRζ in lupus T cells through HRES-1/Rab4. Mitochondrial 
hyperpolarization is associated with depletion of ATP, which predisposes T cells to necrosis. In turn, necrotic materials released from T cells activate 
monocytes and dendritic cells. Solid arrows indicate processes upregulated by NO, while broken lines indicate processes down-regulated by NO. 
APC, antigen-presenting cell; DAG, diacylglycerol; IP3, inositol-1,4,5-triphosphate; LAT, linker for activation of T cells; MHC, major histocompatibility 
complex; PIP2, phosphatidylinositol 4,5-biphosphate; PLC, phospholipase C.
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Page 2 of 6cells, T helper 1 (Th  1) and Th  2 cells, characterized by 
their speciﬁ  c cytokine expression patterns [15]. Th  e  Th  1/
Th  2 balance is considered to be essential in chronic 
inﬂ  ammatory diseases. NO selectively enhances Th  1  cell 
proliferation [16] and represents an additional signal for 
the   induction of T cell subset response. According to our 
data, the NO precursor NOC-18 elicited IFN-γ produc-
tion, whereas the NO synthase inhibitors NG-mono-
methyl-L-arginine and nitronidazole both inhibited its 
production, suggesting a role for NO in regulating IFN-γ 
synthesis [17]. NO preferentially promotes IFN-γ syn  the-
sis and type Th   1 cell diﬀ  erentiation by selective induction 
of IL-12Rβ2 via cGMP. Together, these data indicate that 
NO has a crucial role in the regulation of Th  1/Th  2 
polarization.
Nitric oxide regulates T lymphocyte activation in 
systemic lupus erythematosus
Considerable evidence supports that NO production is 
increased in SLE; for example, serum nitrite and nitrate 
levels were recently reported to correlate with disease 
activity and damage in SLE [18]. According to our 
previous work, NO plays a crucial role in T cell dys-
regulation in SLE [19-21]. Activation-induced rapid Ca2+ 
signals are higher in T cells from patients with SLE [22]; 
in contrast, the sustained Ca2+ signal is decreased in these 
lupus T cells. Interestingly, the mitochondrial membrane 
potential is permanently high in lupus T c  ells [23-25]. 
Lupus and normal T cells produce comparable amounts 
of NO, but monocytes from lupus patients generate 
signiﬁ  cantly more NO than normal monocytes. As it is a 
diﬀ  usible gas, NO produced by neighboring cells may 
aﬀ   ect T cell functions. Accordingly, NO produced by 
mono  cytes contributes to lymphocyte mitochondrial 
dysfunction in SLE [10]. Peripheral blood lymphocytes 
from SLE patients contain enlarged mitochondria, and as 
there are microdomains between mitochondria and the 
endoplasmic reticulum and because mitochondria may 
also serve as Ca2+ stores, this increased mitochondrial 
mass may alter Ca2+ signaling in SLE [10,26]. Although 
NO production was found to be increased in both lupus 
[10] and RA [27], MHP was conﬁ  ned to lupus T cells 
[10,13,28,29]. Th  is diﬀ  erence may be attributed to the 
depletion of intracellular glutathione (GSH) in SLE but 
not in RA or healthy controls [28]. Indeed, low GSH pre-
disposes to MHP in human T cells, as originally des-
cribed by Banki and colleagues [30]. Increased exposure 
to IFN may contribute to the increased NO production of 
lupus monocytes [31].
NO regulates mammalian target of rapamycin 
activity and TCRζ expression in SLE
Th   e mammalian target of rapamycin (mTOR) is a serine/
threonine protein kinase and a sensor of the 
mitochon  drial transmembrane potential that regulates 
protein synthesis, cell growth, cell proliferation and 
survival [32]. Th   e activity of mTOR is increased in lupus 
T cells [29] (Table 1); furthermore, NO regulates mTOR 
activity, which leads to enhanced expression of HRES-1/
Rab4, a small GTPase that regulates recycling of surface 
receptors through early endosomes [29,33]. HRES-1/
Rab4  over  expression inversely correlates with TCRζ 
protein levels. TCR/CD3 expression is regulated by 
TCRζ, and dimin  ished ζ chain expression disrupts TCR 
transport and function [34]. Th   e TCR ζ chain is deﬁ  cient 
in lupus T cells [35,36], although this deﬁ  ciency has been 
shown to be independent of SLE disease activity [3  7,38]. 
Sequencing o  f genomic DNA   and TCRζ transcripts 
showed mutations in the coding region of TCRζ from 
lupus T cells [39]. Th  ere is a direct interaction between 
HRES-1/Rab4, CD4 and TCRζ. Rapamycin   treatment of 
lupus patients reversed the TCRζ deﬁ  ciency  of  lupus 
T cells, and normalized T-cell-activation-induced calcium 
ﬂ   uxing [29]. Th  ese data suggest that NO-dependent 
mTOR activation induces the loss of TCRζ in lupus 
T  cells through HRES-1/Rab4. Several earlier ﬁ  ndings 
indicate that decreased TCRζ chain expression may also 
be independent of NO in SLE [40-44].
Consequences of increased nitric oxide production 
in rheumatoid arthritis
Several studies in patients with RA have documented 
evidence for increased endogenous NO synthesis, 
suggest  ing that overproduction of NO may be important 
in the pathogenesis of RA. Th  e  inﬂ  amed joint in RA is the 
predominant source of NO [45,46]. Several investigators 
found correlations between serum nitrite concentration 
and RA disease activity or radiological progression while 
others did not ﬁ  nd such correlations [47,48]. NOS poly-
morphism has been observed in RA [49]. iNOS is regu-
lated at the transcriptional level, while eNOS and nNOS 
are regulated by intracellular Ca2+. Several diﬀ  er  ent cell 
types are capable of generating NO in the inﬂ  amed syno-
vium, including osteoblasts, osteoclasts, macro  phages, 
ﬁ   broblasts, neutrophils and endothelial cells [50-52]. 
NOS inhibition was reported to decrease disease activity 
in experimental RA [53].
We have shown recently that T cells from RA patients 
produce more than 2.5 times more NO than healthy 
donor T cells (P < 0.001) [27]. Although NO is an impor-
ta nt  physiologic al  mediator of mitochondrial biogenesis, 
mitochondrial mass is similar in both RA and control 
T cells (Table 1). By contrast, increased NO production is 
associated with increased cytoplasmic Ca2+ concentra-
tions in RA T cells (P < 0.001). Furthermore, in vitro 
treat  ment of human peripheral blood lymphocytes or 
Jurkat cells with TNF increases NO production (P = 0.006 
and P = 0.001, respectively), whilst inﬂ  iximab treatment 
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within 6 weeks of the ﬁ   rst infusion (P = 0.005) [27]. 
Increased NO production of monocytes is associated 
with increased mitochondrial biogenesis in lupus T cells, 
while increased NO production of T cells is not asso-
ciated with increased mitochondrial mass in RA. Mono-
cytes express iNOS, while lymphocytes express both 
eNOS and nNOS. Although NO is generated more 
rapidly via the eNOS or nNOS than the iNOS pathway, 
iNOS can generate much larger quantities of NO than 
eNOS and nNOS. Th  us, the lower amount of NO 
generated by T cells compared to monocytes may explain 
the diﬀ  erences in T lymphocyte mitochondrial biogenesis 
that we observed for lupus and RA T cells.
iNOS knockout mice are resistant to IL-1-induced 
bone resorption, suggesting that NO plays a central role 
in the pathogenesis of bone erosions in RA [51,54]. TNF 
blockade decreases iNOS expression in human peripheral 
blood mononuclear cells [55]. Tripterygium wilfordii 
Hook F (TWHF) was also reported to be eﬀ  ective in the 
treatment of experimental arthritis [56]. Th  e speciﬁ  c 
inhibition of iNOS by TWHF is probably responsible for 
the anti-inﬂ  ammatory eﬀ  ects of this medicinal plant. NO 
treatment may lead to necrosis rather than apoptosis by 
decreasing intracellular ATP levels. Th   e release of 
intracellular antigens through necrosis may accelerate 
autoimmune reactions leading to chronic inﬂ  ammation 
[57,58].
Oxidative stress and TCRζ expression in RA T cells - 
the possible role of NO
Reduced GSH levels may contribute to the hypo  respon-
sive  ness of T cells from synovial ﬂ   uid of RA patients 
[59,60]. Th  e expression of the TCR ζ chain protein is 
decreased in synovial ﬂ  uid T cells of RA patients, similar 
to lupus T cells, which may contribute to the above-
mentioned hyporesponsiveness of the synovial ﬂ  uid 
T  cells [61]. TNF-α treatment decreases TCR ζ chain 
expression of T cells [62] in a GSH-precursor-sensitive 
way, showing the role of redox balance in the regulation 
of TCR ζ chain expression. TCRζ overexpression does 
not restore signaling in TNF-α-treated T cells [63]. 
Increased NO production may alter redox balance 
through generating peroxynitrite following its reaction 
with superoxide. In this way NO may contribute to the 
decreased TCR ζ chain expression of T lymphocytes 
from synovial ﬂ  uid [61]. Importantly, FcR gamma substi-
tutes for the TCR ζ chain in SLE T cells [64], which may 
explain the enhanced T-cell-activation-induced Ca2+ 
ﬂ  uxing. Th   e potential role of NO in the regulation of FcR 
gamma expression clearly needs further investi  gation.
Th17 and regulatory T cells
Recently, the Th  1/Th  2 paradigm has been updated 
follow  ing the discovery of a third subset of Th   cells, 
known as Th  17 cells. Th  17 cells have been identiﬁ  ed as 
cells induced by IL-6 and TGF-β and expanded by IL-23 
[65]. Similarly to Th   1 and Th   2 subsets, Th  17  development 
relies on the action of a lineage-speciﬁ  c  transcription 
factor. Th   17 cells have emerged as an independent subset 
because their diﬀ  erentiation was independent of the Th  1 
and Th  2 promoting transcription factors T-bet, STAT1, 
STAT4 and STAT6. ROR-γt, RORα and STAT3 appear to 
be critical for the development of Th   17 cells. Th  17  cells 
produce IL-17 and are thought to clear extracellular 
pathogens that are not eﬀ  ectively handled by either Th  1 
or Th  2 cells, and have also been strongly implicated in 
allergic diseases [66]. In addition to IL-17, Th  17 cells 
produce other proinﬂ  ammatory cytokines such as IL-21 
and IL-22. Increased levels of IL-17 have been observed 
in patients with RA. Indeed, IL-17 can directly and 
indirectly promote cartilage and bone destruction. IL-17-
deﬁ   cient mice develop attenuated collagen-induced 
arthritis. Th  e role of NO in IL-6- and TGF-β-induced 
Th   17 cell diﬀ  erentiation has not been studied yet.
Regulatory T cells (Tregs) represent a subset of T cells 
involved in peripheral immune tolerance. Th  ere are at 
least three major types of Tregs with overlapping func-
tions: Th  3, Treg1, and CD4+CD25+ Tregs. CD4+CD25+ 
Tregs (naturally occurring cells or nTREGs) are the best 
characterized, principally because it is relatively easy to 
obtain large numbers of these cells. Tregs seem to have 
Table 1. Nitric oxide-induced T cell functions in sysemic lupus erythematosus and rheumatoid arthritis
Altered T cell function  SLE  RA
Mitochondrial hyperpolarization and biogenesis  Higher [10]  Normal [27]
T lymphocyte NO production  Normal [10]  Increased [27]
TCR-induced rapid and sustained Ca2+ signal  Rapid-increased, sustained-decreased [10]  Normal [22]
TCRζ expression  Decreased [34]  Decreased [61]
mTOR activity  Increased [29]  Not known
ATP level  Decreased [28]  Normal [28]
Monocyte NO production  Increased [10]  Increased [46]
mTOR, mammalian target of rapamycin; NO, nitric oxide; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TCR, T cell antigen receptor.
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reported that NO, together with anti-CD3, induces the 
proliferation and sustained survival of mouse CD4+CD25- 
T cells, which became CD4+CD25+ but remained Foxp3-. 
Th   is previously unrecognized population of Tregs 
(NO-Tregs) downregulated the proliferation and function 
of freshly puriﬁ  ed CD4+CD25- eﬀ  ector cells in vitro and 
suppressed colitis- and collagen-induced arthritis in mice 
in an IL-10-dependent manner [67]. Th  e existence of 
human NO-Tregs has not been investigated yet. 
Although NO profoundly alters T cell activation and 
Th  1/Th  2 balance, the precise role of NO in Th  17 and 
Treg diﬀ    erentiation is not known.
Conclusion
Whilst NO plays a central role in many physiological 
processes, its increased production is pathological. NO 
mediates many diﬀ   erent cell functions at the site of 
synovial inﬂ   ammation, including cytokine production, 
signal transduction, mitochondrial functions and apop-
tosis (Table 1). Th  e  eﬀ  ects of NO depend on its concen-
tration. Increased NO production plays an important 
role in the pathogenesis of both SLE and RA. Further 
studies are needed to determine the cellular and mole-
cular mechanisms by which NO regulates immune cell 
functions. NOS inhibition may represent a novel thera-
peutic approach in the treatment of chronic autoimmune 
diseases.
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